Cell Therapy for Uveal Melanoma

Cesar Gentille Sanchez, Thomas Pfeiffer, Bilal A. Omer

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review


Metastatic uveal melanoma remains a therapeutic challenge due to its poor response to conventional treatments. Adoptive cell therapies with T cells and other immune effector cells have proven effective in hematological cancers and hold promise for patients with uveal melanoma. For these therapies, immune cells are isolated from the tumor microenvironment and expanded or genetically engineered from peripheral blood T cells to recognize a target present in the tumor cells and stimulate a response. Though cell therapy research remains ongoing in solid tumors, this strategy may improve outcomes for cancers like metastatic uveal melanoma that require new treatment modalities. In this chapter, we review the basics of adoptive cell therapy, focusing on potential targets and outcomes from published preclinical and clinical research in uveal melanoma.

Original languageEnglish
Title of host publicationUveal Melanoma
Subtitle of host publicationBiology and Management
PublisherSpringer International Publishing
Number of pages13
ISBN (Electronic)9783030781170
ISBN (Print)9783030781163
StatePublished - Jan 1 2021


  • CAR-T cells
  • Cellular therapy
  • TCR-engineered cells
  • TILs
  • Uveal melanoma


Dive into the research topics of 'Cell Therapy for Uveal Melanoma'. Together they form a unique fingerprint.

Cite this